Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
KA Fairman, LE Davis, DA Sclar - Therapeutics and Clinical Risk …, 2017 - Taylor & Francis
Background Inconsistency of real-world medication use with labeled indications may affect
cost and clinical value of pharmacotherapy. PCSK-9 inhibitors are labeled in the US for use …
cost and clinical value of pharmacotherapy. PCSK-9 inhibitors are labeled in the US for use …
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug
G Gervasini, NR Robles - Expert Opinion on Investigational Drugs, 2017 - Taylor & Francis
Introduction: Patients with renal dysfunction are at a higher risk of cardiovascular disease
(CVD), which often shares manifestations with heart failure (HF). Last year, the FDA …
(CVD), which often shares manifestations with heart failure (HF). Last year, the FDA …